HC Wainwright Predicts Higher Earnings for Cabaletta Bio

Cabaletta Bio, Inc. (NASDAQ:CABA) – Research analysts at HC Wainwright boosted their FY2026 EPS estimates for Cabaletta Bio in a research note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($1.26) per share for the year, up from their prior estimate of ($1.35). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q4 2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.27) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($0.54) EPS and FY2029 earnings at ($0.53) EPS.

CABA has been the subject of a number of other reports. TD Cowen upgraded shares of Cabaletta Bio to a “strong-buy” rating in a report on Monday, August 24th. William Blair raised Cabaletta Bio to a “strong-buy” rating in a research report on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Thursday, October 15th. Wall Street Zen raised Cabaletta Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Wells Fargo & Company cut their price objective on Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a research report on Friday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Cabaletta Bio presently has an average rating of “Moderate Buy” and a consensus price target of $14.33.

Cabaletta Bio Trading Up 15.4%

Shares of CABA opened at $1.50 on Tuesday. Cabaletta Bio has a one year low of $1.18 and a one year high of $4.23. The company’s fifty day moving average price is $2.09 and its 200 day moving average price is $2.82.

Cabaletta Bio (NASDAQ:CABA) last posted its earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04.

Institutional Investors Weigh In On Cabaletta Bio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Private Advisor Group LLC increased its holdings in shares of Cabaletta Bio by 22.4% during the 1st quarter. Private Advisor Group LLC now owns 18,025 shares of the company’s stock worth $48,000 after purchasing an additional 3,300 shares during the period. Legal & General Group Plc acquired a new position in shares of Cabaletta Bio during the second quarter valued at about $34,000. HighTower Advisors LLC bought a new stake in shares of Cabaletta Bio in the second quarter valued at about $34,000. WINTON GROUP Ltd lifted its stake in shares of Cabaletta Bio by 76.5% in the second quarter. WINTON GROUP Ltd now owns 27,000 shares of the company’s stock valued at $84,000 after buying an additional 11,700 shares during the period. Finally, Kestra Advisory Services LLC bought a new stake in shares of Cabaletta Bio in the first quarter valued at about $32,000.

Key Cabaletta Bio News

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts across 2026–2029, reflecting smaller expected losses, and reiterated its Buy rating with a $16 price target. For example, its FY2027 loss estimate improved to $1.02 per share from $1.29. Cabaletta Bio analyst coverage
• Positive Sentiment: New rese-cel Phase 1/2 results were encouraging: all six dermatomyositis patients maintained moderate-to-major responses without immunomodulators through one year, with most also off steroids. This may strengthen the case for the therapy, though the data are early-stage. Rese-cel Phase 1/2 data
• Neutral Sentiment: Citigroup cut its price target to $8 but maintained a Buy rating, leaving a positive recommendation while signaling a more cautious valuation view. Citigroup price-target update
• Negative Sentiment: A separate analyst reduced its FY2030 EPS estimate, a counterpoint to HC Wainwright’s improved forecasts. FY2030 EPS estimate change

About Cabaletta Bio

Cabaletta Bio, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company’s approach is designed to selectively eliminate disease-causing immune cells and potentially provide durable disease remission rather than relying on continuous immunosuppression.

Its lead investigational product, CABA-201, is an autologous, fully human CD19 chimeric antigen receptor T-cell therapy designed to target and eliminate CD19-positive B cells.